Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)

Latest news

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    Nucala was the first IL-5 inhibitor to reach the market in 2015, and made £344m ($465m) in sales last year. ... IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic

  • NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

    Despite the confidential discount on Dupixent’s list price of £1, 264.89 per pack of two syringes of the IL-4 and IL-13 inhibitor - developed with Regeneron - the cost

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics